Acquires

AbCellera Acquires TetraGenetics to Enhance its Capabilities for Developing Antibodies

Shots: AbCellera acquires TetraGenetics in an all-cash transaction that includes up front, milestones based on the achievement of technical milestones related to the development of therapeutics The acquisition will combine TetraGenetics’ capabilities with AbCellera’s technology to provides an optimized protein source for AbCellera’s Abs discovery across a range of therapeutic areas. The technology has the …

AbCellera Acquires TetraGenetics to Enhance its Capabilities for Developing Antibodies Read More »

MSD Animal Health Acquires LICA’s Assets to Enhance its Dairy Farm Management Solutions

Shots: MSD acquires the LICA’s assets for $27.64M. The transaction is expected to be complete on Jun 11, 2021 The acquisition will boost MSD’s veterinary medicines, vaccines, and health management solutions/ services, and Allflex Livestock Intelligence’s digitally connected identification, traceability, and monitoring products to benefit farmers and veterinarians LICA’s product portfolio joins Allflex Livestock Intelligence …

MSD Animal Health Acquires LICA’s Assets to Enhance its Dairy Farm Management Solutions Read More »

SparingVision Acquires GAMUT Therapeutics to Expands its Novel Ocular Disease Pipeline

Shots: The acquisition expands SparingVision’s ocular genomic medicine pipeline with the addition of GAMUT’s lead product SPVN20, which is a novel, mutation-agnostic gene therapy, focuses on restoring the function of dormant cone cells in the retina. The acquisition is expected to close in Q2’21 SparingVision plans to evaluate the therapeutic synergy with a combination of …

SparingVision Acquires GAMUT Therapeutics to Expands its Novel Ocular Disease Pipeline Read More »

Merck KGaA Acquires AmpTec to Strengthen its mRNA Capabilities for Vaccines, Treatments and Diagnostics

Shots: The acquisition will integrate AmpTec’s PCR-based mRNA technology with Merck’s expertise in lipids manufacturing, providing combine offering across mRNA value chain The deal will expand Merck’s capabilities to develop & manufacture mRNA for use in vaccines, treatments, and diagnostics applicable in COVID-19 and many other diseases. Additionally, AmpTech’s diagnostic business focusing on customized long …

Merck KGaA Acquires AmpTec to Strengthen its mRNA Capabilities for Vaccines, Treatments and Diagnostics Read More »

Stryker Acquires OrthoSensor and its Knee Surgery Sensor Technology

Shots: Stryker acquires OrthoSensor and its Verasense intraoperative sensor tech, enhancing the ortho giant’s Mako robots The acquisition allows Stryker to empower surgeons with comprehensive data-driven solutions. The sensor tech will boost Mako surgical robotics systems, enhancing workflow through one complete data-driven feedback mechanism Moreover, OrthoSensor’s MotionSense remote patient monitoring wearables and mobile application combined …

Stryker Acquires OrthoSensor and its Knee Surgery Sensor Technology Read More »

Philips to Acquire BioTelemetry for ~$2.8B

Shots: Philips to acquire all outstanding shares of BioTelemetry and its wearable heart-tracking devices for $72/ share in cash with a 16.5 % premium to a closing price of BioTelemetry on Dec 17, 2020, making a total value ~$2.8B. The transaction is expected to be completed in Q1’21 The acquisition complements Philips’ cardiac care portfolio …

Philips to Acquire BioTelemetry for ~$2.8B Read More »

AstraZeneca to Acquire Alexion for $39B

Shots: Alexion to receive $60M in cash and 2.1243 ADSs (each ADS represents ½ ordinary share of AstraZeneca) for each Alexion share. The deal values Alexion at $175/ share with a 45% premium to the closing price on Dec 11, 2020 Alexion will own ~15% of the combined company. The acquisition will bolster AstraZeneca’s footprints …

AstraZeneca to Acquire Alexion for $39B Read More »

Boehringer Ingelheim to Acquires NBE-Therapeutics ~ $1.5B

Shots: Boehringer Ingelheim to acquire all shares of NBE-Therapeutics for ~$1.434B which include contingent clinical and regulatory milestones. The transaction is expected to be closed in Q1’21 The acquisition will add NBE-Therapeutics’ ROR1-directed ADCs including NBE-002 which is currently in P-I studies for TNBC and other solid tumors NBE-Therapeutics’ iADC platform will add exceptional tumor-targeting …

Boehringer Ingelheim to Acquires NBE-Therapeutics ~ $1.5B Read More »

Boehringer Ingelheim to Acquires Labor Dr. Merk & Kollegen for Boosting its Next Generation Cancer Immunology Program

Shots: The acquisition will enable Boehringer Ingelheim to expand and accelerate its comprehensive program for the development of ATMP-based immuno-oncology therapies including the VSV with modified GP platform and cancer vaccines platforms The addition of Labor Dr. Merk & Kollegen’s site will enable Boehringer Ingelheim to further strengthen its oncolytic virus and cancer vaccine development …

Boehringer Ingelheim to Acquires Labor Dr. Merk & Kollegen for Boosting its Next Generation Cancer Immunology Program Read More »

Elsevier Acquires Shadow Health

Shots: Elsevier acquires Shadow Health to enhance its extensive portfolio and clinical practice offerings for HCPs during a time of continued growth in telehealth Elsevier works with healthcare educators to prepare students, nursing and HCPs and provide innovative learning tools and analytics that improve educational outcomes and help prepare students for healthcare practice  The acquisition …

Elsevier Acquires Shadow Health Read More »

Exactech Acquires Muvr and it’s Digital Health Tech for Orthopedic Practices

Shots: Exactech has acquired intelligent patient wearables and digital communication solutions maker Muvr Labs to expand its Active Intelligence platform of smart technologies portfolio The Muvr platform includes patient wearables, mobile device applications, and chatbot texting, allowing the surgeons to remotely monitor patient recovery Exactech expects a pilot launch of the Muvr technology in early …

Exactech Acquires Muvr and it’s Digital Health Tech for Orthopedic Practices Read More »

Janssen Acquires Rights to Hemera’s HMR59 for Late-Stage Age-Related Macular Degeneration

Shots: Janssen acquires rights to Hemera’s HMR59, administered as a one-time, outpatient, IVT inj. to help preserve vision in patients with geographic atrophy The acquisition will boost Janssen’s eye disease portfolio & strengthens its gene therapy capabilities HMR59 is designed to increase the ability of retina cells to make a soluble form of CD59, helping …

Janssen Acquires Rights to Hemera’s HMR59 for Late-Stage Age-Related Macular Degeneration Read More »

BD Acquires the Medical Business Assets of CUBEX

Shots: The acquisition expands the BD’s medication management offerings into the care continuum space and provides deeper integration with EHRs The Medical Business of CUBEX’s key offering is a cloud-based software supporting decentralized medication management and provides unique features specialized for pharmacists and nurses across the care continuum With the acquisition, 40 CUBEX’s associates will …

BD Acquires the Medical Business Assets of CUBEX Read More »

UCB Acquires Handl Therapeutics to Augment its Gene Therapy Portfolio

Shots: The acquisition will bolster UCB’s pipeline program, capabilities, and platforms in the gene therapy space. The Handl Therapeutics will continue to be based in Leuven, Belgium while working closely with UCB’s international research teams In addition, the UCB collaborated with Lacerta to focus on CNS diseases, under which Lacera will lead research, preclinical activities, …

UCB Acquires Handl Therapeutics to Augment its Gene Therapy Portfolio Read More »

Coloplast Acquires Nine Continents Medical

Shots: Coloplast has acquired implantable tibial nerve stimulation (ITNS) treatment developer Nine Continents Medical for $145M upfront and an additional contingent milestone. ITNS is developed for overactive bladder (OAB) Coloplast expected to initiate clinical studies of ITNS in 2021 with the goal to obtain pre-market approval for a Class III device in the US and …

Coloplast Acquires Nine Continents Medical Read More »

Medtronic Expands ENT Portfolio with the Acquisition of Ai Biomed and the Approval of NIM Vital Nerve Monitoring System

Shots: Medtronic has expanded its portfolio of technologies focusing on improving the safety of head and neck surgeries with the acquisition of Ai Biomed and the US FDA’s 510(k) clearance of NIM Vital nerve monitoring system The NIM Vital nerve monitoring system enables physicians to identify, confirm, and monitor nerve function to help reduce the …

Medtronic Expands ENT Portfolio with the Acquisition of Ai Biomed and the Approval of NIM Vital Nerve Monitoring System Read More »

Jazz Pharmaceuticals Acquires SpringWorks’ FAAH Inhibitor Program for Post-Traumatic Stress Disorder

Shots: SpringWorks to receive $35M as upfront and $ 375M as clinical, regulatory, and commercial milestones and is eligible to receive royalties on future net sales of PF-04457845. Jazz to get an exclusive license of all assets relating to the FAAH inhibitor program including PF-04457845 The acquisition magnifies Jazz’s neuroscience pipeline into a new disease …

Jazz Pharmaceuticals Acquires SpringWorks’ FAAH Inhibitor Program for Post-Traumatic Stress Disorder Read More »

STADA Expands its Specialty Footprint with the Acquisition of Lobsor Pharmaceuticals

Shots:   STADA acquires Lobsar and its innovative therapy to foster its footprints in specialty pharmaceuticals. The acquisition complements STADA’s portfolio and expertise in the treatment of late-stage Parkinson’s disease With the acquisition, STADA gain rights to a triple fixed combination (levodopa/carbidopa/ entacapone) delivered via modern pump technology, already launched in Nordic countries Levodopa, carbidopa and …

STADA Expands its Specialty Footprint with the Acquisition of Lobsor Pharmaceuticals Read More »

ACADIA Acquires CerSci Therapeutics for $52.5M

Shots: ACADIA acquires all outstanding shares of CerSci for $52.5M. CerSci may receive up to $887M as development, commercialization milestones along with royalties on sales The acquisition will boost ACADIA’s clinical pipeline with the addition of non-opioid pain therapies including CerSci’s lead candidate ACP-044 ACP-044 has demonstrated a promising effect in the P-I study with an …

ACADIA Acquires CerSci Therapeutics for $52.5M Read More »

Bionano Genomics Acquires Lineagen to Facilitate the Clinical Adoption of Saphyr for Digital Cytogenetics

Shots: Lineagen to receive $9.6M consisting of 6,167,510 shares of Bionano’s common stock, ~ $1.7M in cash and assumption of ~$2.9M in liabilities. The acquisition complements Binano by adding leading cytogeneticists, genetic counselors, laboratory operations and billing experts, clinical commercialization experts, and payor contracts The acquisition expands Bionano’s Saphyr genome imaging platform by adding Lineagen’s …

Bionano Genomics Acquires Lineagen to Facilitate the Clinical Adoption of Saphyr for Digital Cytogenetics Read More »

Boehringer Ingelheim Acquires GST to Boost its Stem Cell Capabilities in Animal Health

Shots: Boehringer Ingelheim has acquired Global Stem cell Technology (GST) focusing to strengthen its portfolio capabilities to accelerate innovation and growth The acquisition follows two years of partnership b/w the companies that brought the first-ever registered stem cell-based veterinary medicine (Arti-Cell Forte) in the EU The acquisition of GST will accelerate the development pipeline of …

Boehringer Ingelheim Acquires GST to Boost its Stem Cell Capabilities in Animal Health Read More »

Royalty Pharma Acquires PTC’s Royalty Interest in Risdiplam for $650M

Shots: PTC Therapeutics to receive $650M as upfront in cash in exchange for ~43% of the risdiplam royalties, up to a specified amount while PTC maintains the majority of the risdiplam royalty stream and retains all economics associated with up to ~$400M in remaining regulatory and commercial milestones The collaboration enables PTC to further develop …

Royalty Pharma Acquires PTC’s Royalty Interest in Risdiplam for $650M Read More »